Acute Leukemias VII

Leukemia Cell Biology.- Alterations of DNA Repair: Implications for Leukemia Cell Biology.- Functional Characterization of Leukemic Stem Cells in Acute Myeloid Leukemia.- Involvement of CD34+ Stem Cells in Malignant Transformation in AML and MDS — Genetic Analysis of Sorted Subpopulations by Classical and Molecular Cytogenetics.- Mutations of Mitochondrial DNA as an Early Event in the Pathogenesis of Myelodysplastic Syndromes.- Pilot Study of Pentoxifylline and Ciprofloxacin with or without Dexamethasone Produces Encouraging Results in Myelodysplastic Syndromes.- Expression of Differentiation Antigens on Blast Cells of Acute Myelogenous Leukemia (AML MO-M6).- Cytoplasmatic Expression of CD34 in Acute Leukemia.- Flow Cytometry of Leukocyte Alkaline Phosphatase in Human Hematopoietic Cells.- Biologic Determinants for AML Therapy.- Evaluation of NOD-SCID-Mice for a Human-B-Cell Precursor ALL Xenograft Model.- Flow Cytometric Analysis of Immature Cell Populations in B-Cell Precursor ALL.- Immunophenotypical Subtype of Childhood T-ALL with Favourable Outcome in the COALL 1985–1992 Study Group.- Acute Leukemias with Hybrid Features in Children and Adolescents from Kiev Region (Ukraine).- CD95 (FAS/APO-1) Antigen Expression on the Cells of Myelodysplastic Syndromes, Acute Myelogenous Leukemia and Chronic Myelogenous Leukemia Patients.- The Premyelodysplastic State and the Secondary Hematologic Disorders.- Physiological Events during Ara-C Toxicity Mapped Using Multiparametric Flow Cytometry.- CD95-Mediated Apoptosis in Acute Myeloid Leukemias (AML): Dependence on Maturational State and Growth Characteristics In Vitro.- Structural Properties of the Cell Membrane of Apoptosis-Induced Cells and Leukemic Blast Cells Studied by Electrospinresonance-Spectroscopy.- Simultaneous Detection of Leukemic Blast Cells on PB/BM — Smears Combining May-Gruenwald Giemsa- and APAAP-Staining.- Anomalistic Signaling as a Possible Biochemical Explanation for Discordant Maturation in Chronic Myelogenous Leukemia (CML).- Transformation of Myeloid Cells by the BCR/ABL Oncogene.- New Isoforms of the ZFM 1 Gene: A Growing Family of Signal Transduction and Activator of RNA (STAR) Proteins.- Expression of TIE Receptor Tyrosine Kinase in Leukemia Cell Lines.- Acute Erythroblastic Leukemia is a Rare, but Distinct Subtype of Acute Myeloid Leukemia.- Plasma Cell Leukemia in a 7-month-old Infant.- Myelodysplastic Syndromes in Children: Clinical and Morphological Analysis.- Molecular-/Cytogenetics.- Molecular Screening of Acute Myeloid Leukemia Using Interphase Cytogenetics.- Routinely Prepared Cells for Cytogenetic Analysis Stored at ?20 °C for Several Years can be Used for RT-PCR-Based Detection of Chromosomal Aberrations in Leukemias.- RT-PCR Based Detection of TEL/AML1 Fusion Transcript in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia — A Czech Childhood Leukemia Working Group Experience.- Occurrence of TEL-AML1 Fusion Resulting from (12;21) Translocation in Human Early B-Lineage Leukemia Cell Lines.- Frequent Loss of Heterozygosity on Chromosomes 6q, 9p, 11q or 12p in Childhood Acute Lymphoblastic Leukemia.- Deletions of Human Chromosome Region 6q23-24 in B-Lineage Neoplasias.- Excessive Differentiation of Myeloid Cells in AML-M2 with Translocation 8;21.- The Prognostic Impact of Trisomy 8 in Acute Myeloid Leukemia: Do Accompanying Aberrations Influence Prognosis.- G-CSF Increases the Number of Trisomy 8 Metaphases in Vitro in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome.- The Karyotype in MDS — Cytogenetic Profile, Clinical Correlations and Prognostic Implications in 362 Patients with MDS.- Cytokines and Biomodulation.- Vitamin D3 and Retinoid Mediated Inhibition of Leukemic Cells.- Growth Factors in the Treatment of Acute Lymphoblastic Leukemia.- Control of Leukemia Proliferation in vivo in Patients: In vivo Cytokine Production.- Hematopoietic Growth Factors: Supportive and Priming Effects in AML.- The Role of Growth Factors in the Treatment of AML.- Growth Factors in Elderly Patients with Acute Myeloid Leukemia.- The Role of Growth Factors in Myelodysplastic Syndromes: Biological and Clinical Factors.- Cinical Trials of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF).- Increased Numbers of Progenitor Cells in the Apheresis Product of Patients Randomised to Receive Increasing Doses of Stem Cell Factor (r-metHuSCF) Administered in Combination with Chemotherapy and a Standard Dose of Filgrastim (r-metHuG-CSF).- The Influence of Surface Receptors for G + GM-CSF, IL-3 and SCF and S-Phase Recruitment of AML Cells on Response to First Phase Chemotherapy.- SHc Overexpression Induces Selective Hypersensitivity to GM-CSF and Prevents Apoptosis of the GM-CSF-Dependent Acute Myelogenous Leukemia Cell Line GF-D8.- ICAM-1 Levels Correlations with Cytokine (IL-1, IL-6 and TNF) Production During the Course of Acute Lymphoblastic Leukemia (ALL) in Children.- High Serum IGFBP-2 in Acute Lymphoblastic Leukemia (ALL) may be an Indication for an Increased Risk of Relapse.- Thrombopoietin Supports the Continuous Growth of Cytokine-Dependent Human Leukemia Cell Lines.- Generation of Active Oxygen Forms by Neutrophils and Granulocytopoiesis in Patients with Acute Lymphoblastic Leukemia under Therapy with Use of G-CSF.- Drug Resistance.- Lineage-Tropism of Murine Leukemia Virus Enhancer Activity within the Hematopoietic System.- Retrovirus and Adenovirus-Mediated Interferon Gene Transfer into Hematopoietic Stem Cells (CD34+) of Normal and Chronic Myelogenous Leukemia.- AML in the Elderly: A Biologically Distinct Disease in which MDR1 Expression and Unfavorable Cytogenetics Contribute to Poor Clinical Response. Studies of the Southwest Oncology Group.- Pharmacological Modulators and Alternate Mechanisms of Multidrug Resistance.- Some Reflections on P-Glycoprotein Expression in Acute Leukemia.- In Acute Myeloid Leukemia only the Coexpression of at Least Two Proteins Including P-Glycoprotein, the Multidrug Resistance-Related Protein MRP, bd-2, Mutant p53 and Heat-Shock Protein 27 is Predictive for the Response to Induction Chemotherapy.- Human P-Glycoprotein/MDR1-Gene Product: Surprising Potential for Nuclear Localization and Coupling to Intracellular Growth Factor Signalling.- Treatment of Poor Prognosis Acute Myelogenous Leukemia with PSC-833 and Mitoxantrone, Etoposide, Cytarabine.- Approaches to Overcome Multidrug Resistance: PSC and CdA/ara-C Combination Chemotherapy.- Zidovudine Induces Resistance to Antineoplastic Agents and Alterations in Apoptosis in T-Cell Lymphoma Cells.- Idarubicin Activity Against Multidrug Resistant (mdr-1+) Cells is Increased by Cyclosporin A.- Protection of Marrow from Methotrexate Toxicity by Gene Transfer of Mutant Forms of Dihydrofolate Reductase into Hematopoietic Progenitor Cells.- In Vitro Drug Resistance in Childhood Acute Myeloid Leukemia: A Preliminary Analysis.- Correlation of in Vitro Drug Sensitivity with Clinical Outcome in Adult AML.- Drug Resistance Testing of Acute Myelogenous Leukemia in Adults — Initial Results with the MTT Assay.- Predictive Value of Pretherapeutic In-Vitro Chemosensitivity Testing in Adult AML.- Functional Studies of Daunorubicin Transport in Human Leukemic Cells.- Pharmacokinetics.- Pharmacokinetics and Pharmacodynamics of Asparaginase.- Asparagine Synthetase in Pediatric Acute Leukemias: AML-M5 Subtype Shows Lowest Activity.- Pharmacokinetic Basis for an Oral Chemotherapy with Idarubicin and Etoposide: Dose-Dependent Biological Effects of Topoisomerase-II-Inhibitors.- Involvement of ICE-Like Proteases in Gemcitabine-Induced Programmed Cell Death.- Effect of Combined Treatment with 4-Hydroper-oxycyclophosphamide and Fludarabine on Cytotoxicity and Repair of Damaged DNA.- Enhanced Effects of Adriamycin by Combination with a New Ribonucleotide Reductase Inhibitor, Trimidox, in Murine Leukemia.- Pharmacological Aspects of the Oral Application of Etoposide.- Pharmacokinetics and Metabolism of Low-Dose ATRA in Children — First Observations.- In Vitro Monitoring of Asparaginase: Unphysiological Alteration of the Culture Medium.- Pharmacokinetics and Mechanisms of Action of Cytosine Arabinoside.- Modulation of Ara-C Metabolism to Improve AML Response.- Response of AML Blasts to Ara-C: Role of BCL-2 in the Regulation of Drug Sensitivity.- Ara-C Metabolism in Fresh Leukemic Blasts/Normal Bone Marrow/Hematopoetic Stem Cells and its Impact on the Lipid Composition of Leukemic Cells (HL60).- Interaction of 1-?-D-arabinofuranosylcytosine with Lipid Metabolism.- Cellular Metabolism and T-ALL Specificity of Arabinosylguanine: a Review.- Modulation of Ara-C Cytotoxicity by Coadministration with Antisignalling Drugs in HL60 and Ara-C-Resistant HL60/Ara-C Cells.- Cytotoxic Activity and Pharmacology of an Ara-CMP Prodrug in T-leukemic Sublines Resistant to Ara-C.- Retinoids Modulate Ara-CTP Pharmacology in the HL-60 Acute Leukemia Cell Line.- Induction of Apoptosis in Vitro by ARA-C, VP-16, MITOX, DNR, IDA and FLU in Myeloid Leukemic Cells.- Comparison of Hydroxyurea, Fludarabine and Cladribine in Modulating Ara-C Pharmacology in the Ara-C-Sensitive and Resistant HL-60 and HL-60/Ara-C Cell Lines.- Primary Resistance to Ara-C in AML Progenitor Cells and its Modulation by Cytokines.- Gemcitabine-Mediated Enhancement of Cellular Cytarabine-5-Triphosphate (ara-CTP) Accumulation.- Immunotherapy.- Experimental Basis for Immunotherapy of Metastases.- Gene Marking to Establish the Biology of Minimal Residual Disease and Relapse.- Adoptive Immunotherapy in the Treatment of Post-Transplant Relapse and Epstein-Barr Virus Lymphoproliferative Disorders.- Induction of Graft-versus-Leukemia-Activity after Peripheral Blood Progenitor Cell Transplantation (PBPCT).- Induction and Post-Remission Therapy in Acute Myeloid Leukemia: Experience of the Eastern Cooperative Oncology Group (ECOG).- Cellular Immunotherapy of Cancer: Adoptive Transfer of Monocyte-Derived Tumorcytotoxic Macrophages.- GM-CSF Stimulation of Immune Response in Minimal Residual Cancer.- T-Cell-Mediated Immunity against B-Cell Malignancies: Preclinical Results and Translation into a Novel Immunotherapeutic Approach for B-Cell Malignancies.- Treatment of Childhood ALL.- Treatment of Children with Relapsed Acute Lymphoblastic Leukemia Studies of the BFM Study Group.- Experience with BFM 1990 Protocol Treatment of Recurrent Childhood Lymphoblastic Leukemia. Report of the Polish Children’s Leukemia/Lymphoma Study Group.- Modified New York Regimen for Children with High Risk Acute Lymphoblastic Leukemia (HR-ALL). Preliminary Results..- Treatment of Adult ALL.- Treatment of High-Risk Acute Lymphoblastic Leukemia. Preliminary Results of the Protocol PETHEMA ALL-93.- Idarubicin and Ifosfamide in the Treatment of Refractory and Relapsed Acute Lymphoblastic Leukemia.- Treatment of Ph+ and t(4;11)+Acute Lymphoblastic Leukemia in Adults.- Philadelphia (Ph)-chromosome-negative Peripheral Blood Stem Cells can be Mobilized in the Early Phase of Recovery after a Myelosuppressive Chemotherapy in Ph-Chromosome-Positive Acute Lymphoblastic Leukemia.- Prolonged Remission in Adult B-ALL (L3) and Advanced Burkitt's Lymphoma Using Acute Leukaemia Regimens: Study of 34 Patients.- Autologous Bone Marrow Transplantation in Adult Lymphoblastic Leukaemia — Single Centre Experience.- Cranial Computed Tomographic Scans at Diagnosis in Children with Leukemia.- Treatment of Childhood AML.- Autologous Bone Marrow Transplantation in First Complete Remission as Intensification Therapy in Children with High Risk AML - Results of the Pediatric Cooperative AML Trial 1987-1992 in East Germany.- Risk Factors for Survival in Children with Refractory AML Treated According to AML Relapse Strategies.- Treatment of Adult AML.- Intensified Therapy of AML — The Role of the HAM Combination.- Recent Studies in AML, RAEB-t, and RAEB at M. D. Anderson Hospital.- FLAG-Ida, an Effective Regimen for High Risk AML.- Chemotherapy with Idarubicin, Ara-C, VP-16, Amsacrine, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for Patients with High-Risk Acute Myeloid Leukemia: a 3-Years Follow Up.- Time Sequential Therapy (TAD-HAM) for Secondary AML with and without G-CSF Priming and Support — a Randomized Study.- Oral Chemotherapy for Acute Myeloid Leukaemia.- Oral Idarubicin in the Treatment of AML.- Acute Myeloid Leukemia in Patients Aged over 75 Years: Clinico-Hematological Characteristics and Treatment Results.- Improved Results of AML Treatment in Adults during a 12-Year Period. A Population-Based Study.- Stratification of Postremission Therapy in Adult Acute Myeloid Leukemia According to the Karyotype — Preliminary Results of the Multicenter Treatment Trial AML HD93.- Continuous Infusion of Mitoxantrone Combined with High Dose Cytarabine (c-HAM) in de Novo AML.- All-Trans Retinoic Acid (ATRA) Combined with Double Induction Strategy in Acute Promyelocytic Leukemia (APL). Preliminary Results.- The Effect of ATRA (Roche) on Clinical and Laboratory Parameters in 36 APL Patients — Polish Multicenter Retrospective Analysis.- Abundance of Auer Bodies and Bilobed Nuclei of Leukemic Cells may be Related to Longer Disease Free Survival of Patients with Acute Promyelocytic Leukemia (M3).- The Influence of Dysplastic Hematopoiesis on the Outcome in Patients with de Novo AML.- Trial to Extract Prognostic Factors Prior to the Start of Induction Chemotherapy for Adult AML.- Stem Cell Transplants in Acute Myeloid Leukaemia (AML).- Blood Stem Cell Transplantation in Acute Myeloid Leukemia.- Peripheral Blood Stem Cell Transplantation During Postremission Treatment of de Novo Acute Myelogenous Leukemia 915.- Myeloablative Chemotherapy and Peripheral Blood Stem Cell Transplantation vs Consolidation Therapy of Acute Myelogenous Leukemia in First Remission.- Treatment of Relapsed and Refractory Acute Myeloid Leukemias — Strategies of the German AML Cooperative Group (AMLCG).- Intermediate Dose Cytarabine and Idarubicin for Salvage Therapy of Acute Myeloid Leukemia.- Superiority of High-Dose over Intermediate-Dose Cytosine Arabinoside (AraC) in the Treatment of Patients with High-Risk Acute Myeloid Leukemia (AML).- Granulocyte Colony-Stimulating Factor Improves the Antileukemic Efficacy of the Sequential High-Dose Cytosine Arabinoside and Mitoxantrone Regimen (S-HAM) in Patients Younger than 60 Years with High-Risk Acute Myeloid Leukemia.- Therapy of Advanced MDS, AML Evolving from MDS, or Secondary AML with Idarubicin/Ara-C, VP-16 Followed by G-CSF-Priming Exhibits High Remission Rate.- Immunomodulation and Therapeutic Effects of a Monotherapy with Interleukin-2 as an Induction Therapy in Patients with poor Prognosis Acute Myeloid Leukemia.- Carboplatin-Based High-Dose Therapy for Refractory Acute Myeloid Leukaemia.- Phase I–II Study of Carboplatin with VP16 and AraC for Poor-Risk-Acute Leukemia.- Minimal Residual Disease.- Detection and Quantification of Minimal Residual Disease in Childhood B-Precursor Acute Lymphoblastic Leukemia by Limiting Dilution and PCR Application.- Monitoring of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia — Preliminary Data from a Prospective Study.- Clonal Chromosomal Abnormalities in the Stem Cell Compartment of a Patient with Acute Myeloid Leukemia in Hematological Complete Remission.- Detection of Minimal Residual Disease in Patients with Acute Myeloid Leukemia.- RT-PCR for the Detection of Minimal Residual Disease in Acute Myeloblastic Leukemia with t(8;21) and t(15;17).- RT-PCR for the Diagnosis of Acute Myeloblastic Leukemia with Inv(16) and Detection of Minimal Residual Disease.- Monitoring of PML-RAR alpha in Patients with Acute Promyelocytic Leukemia (APL) by RT-PCR.- Detection Limits of Malignant Cells with Leukemia Associated Phenotype (LAP) in Acute Myeloid Leukemia.- Supportive Therapy.- Interventional Antimicrobial Therapy in Febrile Neutropenic Patients (PEG Study II).- Management of Infections During Intensified Therapy of Acute Leukemias.- Management of Fever in Adult Hematological Neutropenic Patients: Comparison of Tazocillin + Aminoglykoside versus Ceftazidime + Aminoglykoside in 466 Febrile Episodes.- Management of Febrile Neutropenia in 396 Episodes in Acute Leukemia Patients with Once-Daily Administration of Ceftriaxone.- Failure of Fluconazole Prophylaxis to Reduce Mortality During Treatment for Refractory Acute Myeloid Leukemia: Results of a Phase III Multicenter Study.- Aspergillus terreus Necrotic Chest Skin Lesion in a Case of Acute Myeloid Leukemia.- Local Hydrotherapy as a Treatment Method of Oral Cavity Infections in Children with Acute Leukemias and Lymphomas.- Transplantation.- The Role of BMT in AML in Relation to Prognostic Characteristics.- Early Allogeneic Transplantation Favorably Influences the Outcome of Adult Patients Suffering from Acute Myeloid Leukemia.- Antithymocyte Globulin as Part of the Pretransplant Conditioning Regimen May Reduce Transplant-Related Morbidity and Mortality in Chronic Myelogenous Leukemia Patients Undergoing Allogeneic Bone Marrow Transplantation.- Marrow Transplants from Unrelated Donors for the Treatment of High-Risk Acute Leukemia.- Blood Progenitor Cells and Donor Lymphocyte Transfusion: the New Modes of Marrow Transplantation.- Allogeneic Transplantation of Purified Peripheral Blood Stem Cells from Unrelated Donors.- Ex Vivo Manipulation of Peripheral Blood CD34+ Cells.- Cord Blood Transplantation in Hematopoietic Malignancies.- Interferon in Hematologic Malignancies.- Interferon Alpha and Cytosine Arabinoside in the Treatment of Chronic Myelogenous Leukemia.- Alpha-Interferon Role in the Management of Follicular Lymphoma Patients. The GELA Experience.- Treatment of Centroblastic-Centrocytic and Centrocytic Lymphomas at Advanced Stages — Results of the German Low-Grade Lymphoma Study Group.- Quantitative Assessment of the Impact of Interferon Alpha (IFN) vs. Busulfan vs. Hydroxyurea and of Risk Profile on Survival in Chronic Myelogenous Leukemia (CML).- Interferon Alpha and Beta2 Microglobulin in Multiple Myeloma.- Maintenance with Interferon Alfa in Myeloma.